Skip to main content

ADVERTISEMENT

Larry Blandford, PharmD

Pharma Insights
05/06/2016
We are pleased to present the second installment in our recurring column, Pharma Insights. This month we take a look at an interesting twist in how the use of complementary and companion diagnostics is playing out in...
We are pleased to present the second installment in our recurring column, Pharma Insights. This month we take a look at an interesting twist in how the use of complementary and companion diagnostics is playing out in...
We are...
05/06/2016
Journal of Clinical Pathways
Pharma Insights
05/15/2019
Dr Hennessey relates her past personal experience with cancer care delivery when her mother was receiving chemotherapy for lung cancer, where an issue with care access could have significantly altered her mother’s...
Dr Hennessey relates her past personal experience with cancer care delivery when her mother was receiving chemotherapy for lung cancer, where an issue with care access could have significantly altered her mother’s...
Dr...
05/15/2019
Journal of Clinical Pathways
Pharma Insights
06/20/2016
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The promise in the coming years of a novel therapeutic to slow the progression of the debilitating effects of Alzheimer’s disease (AD) is exciting and represents a monumental step forward in treating patients with...
The...
06/20/2016
Journal of Clinical Pathways
Pharma Insights
06/18/2019
What began as patient call centers for select complex medicines has expanded to a full suite of support services, ranging from financial assistance to patient education: so-called hub services have become ubiquitous...
What began as patient call centers for select complex medicines has expanded to a full suite of support services, ranging from financial assistance to patient education: so-called hub services have become ubiquitous...
What...
06/18/2019
Journal of Clinical Pathways
Pharma Insights
10/12/2016
The use of formulary exclusion lists is expanding—and such lists are beginning to shape the market by further limiting available drugs for narrow therapeutic areas while reducing redundancy of options in broader...
The use of formulary exclusion lists is expanding—and such lists are beginning to shape the market by further limiting available drugs for narrow therapeutic areas while reducing redundancy of options in broader...
The...
10/12/2016
Journal of Clinical Pathways
Pharma Insights
08/19/2019
Value assessment in oncology is an emerging area of interest. Multiple value frameworks have been launched in the past 5 years to help stakeholders analyze the cost-effectiveness, or affordability, of oncology...
Value assessment in oncology is an emerging area of interest. Multiple value frameworks have been launched in the past 5 years to help stakeholders analyze the cost-effectiveness, or affordability, of oncology...
Value...
08/19/2019
Journal of Clinical Pathways
Pharma Insights
11/15/2016
Traditional markets have grown crowded with acceptable treatments for large patient populations, which can limit access for drugs in development for these therapeutic areas. Rather than taking a head-on approach to...
Traditional markets have grown crowded with acceptable treatments for large patient populations, which can limit access for drugs in development for these therapeutic areas. Rather than taking a head-on approach to...
...
11/15/2016
Journal of Clinical Pathways
Pharma Insights
11/18/2019
Gene therapy has sparked significant interest among researchers, health care providers, and patients because it offers the tantalizing possibility of a cure, particularly for rare diseases with a genetic basis. While...
Gene therapy has sparked significant interest among researchers, health care providers, and patients because it offers the tantalizing possibility of a cure, particularly for rare diseases with a genetic basis. While...
Gene...
11/18/2019
Journal of Clinical Pathways
Pharma Insights
12/13/2016
The Affordable Care Act of 2010 has transformed the health care landscape by providing strong incentives to insurers to improve the overall quality of care through the Five-Star Quality Rating System. The success of...
The Affordable Care Act of 2010 has transformed the health care landscape by providing strong incentives to insurers to improve the overall quality of care through the Five-Star Quality Rating System. The success of...
The...
12/13/2016
Journal of Clinical Pathways
Pharma Insights
03/15/2018
Health care has become increasingly digitalized, but until now drugs have escaped digitalization. Advancements in digital technologies are changing how we think about disease management and even disease treatment....
Health care has become increasingly digitalized, but until now drugs have escaped digitalization. Advancements in digital technologies are changing how we think about disease management and even disease treatment....
Health...
03/15/2018
Journal of Clinical Pathways